Blue Eagle Lithium
High Times
Home > Boards > US Listed > Biotechs > Intellipharmaceutics International Inc. (IPCI)

$6.6 million 4th Qtr 2017 Tight Estimate

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
tilator Member Profile
 
Followed By 0
Posts 693
Boards Moderated 0
Alias Born 09/14/17
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/18/2018 5:20:51 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/17/2018 2:54:24 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/17/2018 6:06:31 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/16/2018 5:31:22 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/16/2018 5:29:03 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/15/2018 5:28:49 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/15/2018 3:52:11 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/15/2018 3:51:43 PM
Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) Edgar (US Regulatory) - 10/15/2018 7:35:39 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/12/2018 4:51:41 PM
Registration of Additional Securities (up to 20%, Foreign Issuer) (f-1mef) Edgar (US Regulatory) - 10/12/2018 6:08:11 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/12/2018 6:07:52 AM
Securities Registration (foreign Private Issuer) (f-1/a) Edgar (US Regulatory) - 10/11/2018 6:42:39 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/11/2018 6:36:13 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/11/2018 6:06:49 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 10/5/2018 5:43:55 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/5/2018 7:16:25 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/5/2018 7:08:59 AM
Securities Registration (foreign Private Issuer) (f-1/a) Edgar (US Regulatory) - 10/5/2018 6:19:33 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 10/1/2018 8:12:58 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/1/2018 8:06:15 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/21/2018 4:43:58 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 9/21/2018 4:35:33 PM
Securities Registration (foreign Private Issuer) (f-1) Edgar (US Regulatory) - 9/20/2018 5:37:43 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 9/13/2018 9:17:54 AM
tilator   Friday, 11/10/17 05:12:56 PM
Re: AngeloFoca post# 31212
Post # of 37556 
Quote:
$6.6 million 4th Qtr 2017 Tight Estimate



You are right, but the big question is why on earth MNK can sell only 1-2% compared to Accord and Lupin sales even though they got approval together?

This leaves much to gain to MNK.

If MNK got 1000% growth right now, it still would sell only 10% compared to Accord and 20% compared to Lupin.

Well - the numbers are prescription counts, not dollars, but anyway. I suppose you got the point.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist